SCHEMBL7084929

SCHEMBL7084929

CC(C)Oc1cccnc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
ALOX15 P16050 2/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
BLM P54132 1/20 0.50
AGER Q15109 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LMNA P02545 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
BRD4 O60885 1/20 0.45
BRPF1 P55201 1/20 0.45
MYC P01106 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.45
CYP1A2 P05177 1/20 0.45
ACHE P22303 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5513970 0.87 KMT2A (0.54) KDM4EALDH1A1MAPTALOX15CYP3A4
SCHEMBL30598073 0.85 IRAK4 (0.56) KDM4EALDH1A1LMNATDP1BRD4
SCHEMBL7083185 0.83 L3MBTL1 (0.54) KDM4EALDH1A1ALOX15L3MBTL1LMNA
SCHEMBL8515175 0.83 KDM4E (0.50) KDM4EALDH1A1MAPTALOX15CYP3A4
SCHEMBL8884700 0.82 KDM4E (0.50) KDM4EALDH1A1MAPTALOX15CYP3A4
SCHEMBL3712897 0.82 BRD4 (0.43) KDM4EALDH1A1MAPTALOX15CYP3A4
SCHEMBL19539319 0.82 BRD4 (0.51) KDM4EALDH1A1MAPTLMNATDP1
SCHEMBL19531976 0.82 BRD4 (0.51) KDM4EALDH1A1MAPTLMNATDP1
SCHEMBL17028424 0.81 KDM4E (0.49) KDM4EALDH1A1MAPTALOX15CYP3A4
SCHEMBL17028426 0.81 KDM4E (0.49) KDM4EALDH1A1MAPTALOX15CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN disclosed
CN-111630051-B Olefin spiro compounds as farnesol X receptor modulators 百时美施贵宝公司 2023-12-26 CN disclosed
CN-106164064-B Substituted cyclopentane, tetrahydrofuran and pyrrolidines as orexin receptor antagonists 武田药品工业株式会社 2019-03-22 CN disclosed
US-9790220-B2 Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-17 US disclosed
US-20170073340-A1 SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-16 US disclosed
EP-3107907-A1 SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2016-12-28 EP disclosed
CN-106164064-A Substituted cyclopentane, oxolane and pyrrolidine as orexin receptor antagonists 武田药品工业株式会社 2016-11-23 CN disclosed
CN-106008504-A Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels 沃泰克斯药物股份有限公司 2016-10-12 CN disclosed
CN-103403004-B Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INC. (US) 2016-06-01 CN disclosed
WO-2015124934-A1 SUBSITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS TAKEDA CAMBRIDGE LIMITED (GB) 2015-08-27 WO disclosed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073340-A1 SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, NPY1R KDM4E 1089/4885ALDH1A1 762/4885MAPT 1785/4885
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 KDM4E 1768/4885ALDH1A1 145/4885MAPT 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.